Gao Yun, Fang Xiaobin, Zhang Luo, Yin Xiushan
RocRock Biotechnology (Suzhou), Suzhou 215000, China.
Research Center of Bioengineering, the Medical Innovation Research Division of Chinese PLA General Hospital, Beijing 100853, China.
STAR Protoc. 2024 Dec 20;5(4):103350. doi: 10.1016/j.xpro.2024.103350. Epub 2024 Sep 28.
Human-derived macrophages are notoriously difficult to infect with HIV-1-based lentiviruses, posing a limitation to the advancement of chimeric antigen receptor macrophage (CAR-M) therapy. Here, we present a protocol for generating human chimeric antigen receptor (CAR)-engineered macrophages using the viral protein Vpx (encoded by the Sooty Mangabey simian immunodeficiency virus [SIV] and HIV-2 lineages) incorporated into the lentivirus vector, which enhances infection efficiency. We describe steps for cell cultivation, lentivirus production, concentration, infection procedures, and efficiency assessments. This protocol provides a foundation to study macrophage manipulation, especially with CAR or other immune engagers. For complete details on the use and execution of this protocol, please refer to Gao et al..
众所周知,人类来源的巨噬细胞很难被基于HIV-1的慢病毒感染,这对嵌合抗原受体巨噬细胞(CAR-M)疗法的发展构成了限制。在此,我们提出了一种使用整合到慢病毒载体中的病毒蛋白Vpx(由乌黑白眉猴猴免疫缺陷病毒[SIV]和HIV-2谱系编码)来生成人类嵌合抗原受体(CAR)工程化巨噬细胞的方案,该方案可提高感染效率。我们描述了细胞培养、慢病毒生产、浓缩、感染程序和效率评估的步骤。该方案为研究巨噬细胞操作提供了基础,特别是对于CAR或其他免疫衔接器。有关该方案使用和执行的完整详细信息,请参考Gao等人的研究。